Related Experiment Video

Updated: Nov 2, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.7K

Resistance Mechanisms to CDK Inhibition plus Endocrine Therapy Identified

    Cancer Discovery
    |June 12, 2021
    PubMed

    Insights

    In early-stage breast cancer, combining ribociclib with letrozole may lead to estrogen-independent resistance. This finding is crucial for understanding treatment limitations and developing future therapies.

    Area of Science:

    • Oncology
    • Endocrinology
    • Pharmacology

    Background:

    • Early-stage breast cancer treatment often involves endocrine therapy.
    • Estrogen receptor-positive breast cancer is common.
    • Resistance to endocrine therapy remains a clinical challenge.

    Purpose of the Study:

    • To investigate the mechanisms of resistance when ribociclib is combined with letrozole in early-stage breast cancer.
    • To identify estrogen-independent pathways that may emerge under this treatment regimen.

    Main Methods:

    • Analysis of treatment response in preclinical models or patient samples.
    • Molecular profiling to identify signaling pathways.
    • Assessment of estrogen receptor activity and downstream targets.

    Main Results:

    • The combination of ribociclib and letrozole induced the activation of estrogen-independent resistance pathways.
    • Specific molecular alterations were identified that bypass estrogen signaling.

    Conclusions:

    • Ribociclib plus letrozole can lead to the development of estrogen-independent resistance in early-stage breast cancer.
    • Understanding these pathways is essential for overcoming treatment resistance.

    More Related Videos

    Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

    Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

    Published on: October 26, 2015

    11.5K
    Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

    Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

    Published on: December 11, 2017

    7.4K

    Related Concept Videos

    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    5.1K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.5K
    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    7.2K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    8.0K
    M-Cdk Drives Transition Into Mitosis02:15

    M-Cdk Drives Transition Into Mitosis

    Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
    Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
    M cyclin...
    5.8K
    Adaptive Mechanisms in Cancer Cells02:53

    Adaptive Mechanisms in Cancer Cells

    Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
    Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
    6.1K